ZANTAC 25
LOE ApproachingNDAORALTABLET, EFFERVESCENT
Approved
Mar 1994
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZANTAC 25 is an oral effervescent tablet approved in 1994, representing a legacy H2-receptor antagonist formulation. The specific indication is not detailed in available data, but the product class typically treats acid-reflux conditions. The mechanism of action involves H2-receptor antagonism, though specific MOA data is not available for this formulation.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30/100), indicating a contracting team and transition focus toward generic defense or portfolio exits.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings signal a shrinking brand team preparing for loss of exclusivity. Roles on ZANTAC 25 are likely focused on defending market share, managing generic transition, and cost optimization rather than growth or innovation.
Brand ManagerField Sales
Worked on ZANTAC 25 at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.